Skip to main content
. 2009 Oct 12;8:41. doi: 10.1186/1476-511X-8-41

Figure 3.

Figure 3

Ezetimibe reduced a circulating oxidative marker, derivatives of reactive oxidative metabolites (d-ROMs), in patients with atherosclerosis-prone with hypercholesterolemia. Measurements of d-ROMs were assessed before and after 22-week ezetimibe administration in patients with atherosclerosis-prone hypercholesterolemia (n = 14). Bars represent the mean value of the ratio ± SD.